Synovics Pharmaceuticals, Inc.
SYVC
$0.00
$0.000.00%
OTC PK
| 07/31/2009 | 04/30/2009 | ||||
|---|---|---|---|---|---|
| Revenue | -43.82% | -58.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -43.82% | -58.90% | |||
| Cost of Revenue | -22.42% | -38.12% | |||
| Gross Profit | -2,178.14% | -98.81% | |||
| SG&A Expenses | -37.36% | -38.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -29.85% | -34.41% | |||
| Operating Income | 11.07% | -229.82% | |||
| Income Before Tax | 22.05% | -135.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 22.05% | -135.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.05% | -135.46% | |||
| EBIT | 11.07% | -229.82% | |||
| EBITDA | 16.13% | -309.62% | |||
| EPS Basic | 25.30% | -133.25% | |||
| Normalized Basic EPS | 25.13% | -132.51% | |||
| EPS Diluted | 22.65% | -133.25% | |||
| Normalized Diluted EPS | 25.13% | -132.51% | |||
| Average Basic Shares Outstanding | 4.27% | 1.13% | |||
| Average Diluted Shares Outstanding | 4.27% | 1.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||